​

Ernexa Therapeutics Stock (NASDAQ:ERNA)

RevenueOwnershipFinancialsChart
Ernexa Therapeutics by TradingView

Previous Close

$1.29

52W Range

$1.19 - $23.70

50D Avg

$1.68

200D Avg

$3.49

Market Cap

$10.58M

Avg Vol (3M)

$84.87K

Beta

6.74

Div Yield

-

ERNA Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Aug 29, 1991

Website

ERNA Performance

ERNA Financial Summary

Dec 24Dec 23Dec 22
Revenue$582.00K$68.00K-
Operating Income$-15.67M$-21.14M$-33.22M
Net Income$-44.55M$-21.67M$-24.58M
EBITDA$-15.67M$-19.93M$-33.22M
Basic EPS$-3.26$-4.08$-8.06
Diluted EPS$-3.26$-4.08$-8.06

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
ANNXAnnexon, Inc.
ITOSiTeos Therapeutics, Inc.
ENTOEntero Therapeutics, Inc.
REVBRevelation Biosciences, Inc.
CDIOCardio Diagnostics Holdings, Inc.
BIAFbioAffinity Technologies, Inc.